文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

低剂量阈值启动血管加压素对脓毒性休克死亡率的影响:VASSPR集群交叉随机策略试验

Effect of Vasopressin Initiation Threshold on Septic Shock Mortality: The VASSPR Cluster Crossover Randomized Strategy Trial.
PubMed 文献 · JAMA · 2026-10-14
一句话结论在脓毒性休克中,医院层面策略推荐在其它血管加压药较低剂量阈值(0.1 µg/kg/min去甲肾上腺素当量)时启动血管加压素,与较高阈值(0.4 µg/kg/min)相比未降低28天死亡率。

该集群随机交叉试验纳入13家医院、3959例接受血管加压药治疗的脓毒性休克成人患者,比较医院层面推荐在其它血管加压药总剂量达0.1 µg/kg/min去甲肾上腺素当量(低阈值策略)或0.4 µg/kg/min(高阈值策略)时启动固定剂量血管加压素的策略。低阈值策略组68.0%患者接受血管加压素,高阈值组42.7%。结论:低阈值启动血管加压素未改善预后。

要点

  • 对于脓毒性休克成人患者,医院层面推荐在其它血管加压药剂量达0.1 µg/kg/min去甲肾上腺素当量时启动血管加压素,与推荐在0.4 µg/kg/min时启动相比,28天死亡率无显著差异(31.8% vs 33.0%,调整OR 0.98,95%CI 0.87-1.06)。
  • 低阈值策略组血管加压素使用率更高(68.0% vs 42.7%),启动前最大血管加压药剂量中位数更低(0.14 vs 0.34 µg/kg/min去甲肾上腺素当量)。
  • 两组肾脏替代治疗无天数中位数均为29天(IQR -1至29),调整OR 1.01(95%CI 0.91-1.14),无显著差异。
  • 该试验为集群随机交叉设计,13家医院参与,结果支持不强制在较低剂量阈值启动血管加压素,但原文未提供具体的患者层面启动时机建议。

适用人群与场景

  • 纳入:2024年2月1日至2025年7月31日在13家医院(Idaho和Utah)因脓毒性休克接受血管加压药治疗的成人患者,共3959例(中位年龄68岁,48%女性)。
  • 排除:原文未提及具体排除标准。
  • 场景:医院层面策略实施,非急诊/ICU床旁个体化决策;病情阶段为脓毒性休克需血管加压药治疗。

诊断标准与关键阈值

  • 脓毒性休克诊断标准:原文未提及具体诊断标准(如Sepsis-3等)。
  • 启动血管加压素的阈值:低阈值策略推荐当其它血管加压药总剂量达0.1 µg/kg/min去甲肾上腺素或等效剂量时启动固定剂量血管加压素;高阈值策略推荐达0.4 µg/kg/min去甲肾上腺素或等效剂量时启动。
  • 原文未提及启动/停止血管加压素的其他阈值或评分界值。

处置流程与药物剂量

  • 第一步:对脓毒性休克成人患者,按医院随机分配的策略(低阈值或高阈值)决定血管加压素启动时机。
  • 第二步:低阈值策略:当其它血管加压药总剂量达到0.1 µg/kg/min去甲肾上腺素或等效剂量时,启动固定剂量血管加压素(具体剂量原文未提及)。
  • 第三步:高阈值策略:当其它血管加压药总剂量达到0.4 µg/kg/min去甲肾上腺素或等效剂量时,启动固定剂量血管加压素(具体剂量原文未提及)。
  • 原文未提及血管加压素的给药途径、频次、疗程或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:集群随机、集群交叉、实用性临床策略试验;13家医院参与;样本量3959例脓毒性休克成人患者。
  • 干预与对照:医院层面实施低阈值(0.1 µg/kg/min去甲肾上腺素当量)启动血管加压素策略 vs 高阈值(0.4 µg/kg/min)策略;医院首月随机分配(6家低阈值 vs 7家高阈值),之后每月交叉。
  • 关键次要终点:肾脏替代治疗无天数至第28天,两组中位数均为29天(IQR -1至29),调整边际OR 1.01(95%CI 0.91-1.14)。
  • 在可能经历差异管理的患者中(最大血管加压药剂量≥0.07 µg/kg/min去甲肾上腺素当量),低阈值策略组血管加压素使用率68.0%(1034/1521) vs 高阈值组42.7%(651/1526);启动前最大血管加压药剂量中位数分别为0.14(IQR 0.10-0.22) vs 0.34(IQR 0.16-0.42) µg/kg/min去甲肾上腺素当量。
  • 不良事件:原文未提及。

证据类型、等级与局限

  • 证据类型:集群随机交叉实用性临床策略试验(RCT)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:原文未明确列出局限;设计上为集群水平干预,存在实施差异可能,但原文未讨论。

对床旁实践的改变

  • 对于脓毒性休克成人患者,不强制要求在其它血管加压药较低剂量(0.1 µg/kg/min去甲肾上腺素当量)时启动血管加压素,因为与较高剂量(0.4 µg/kg/min)阈值策略相比未降低28天死亡率。
  • 该结果基于医院层面策略比较,不能直接推断个体患者的最佳启动时机;临床决策仍需结合患者具体情况。
  • 原文未提及适用或不适用人群的进一步细分,常见陷阱未提及。

指南或共识出处

  • 原文未提及指南或共识名称;试验注册号:ClinicalTrials.gov Identifier: NCT06217562。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: The optimal vasopressor dose at which to initiate a second vasopressor in patients with septic shock is uncertain.

OBJECTIVE: To compare the effects of hospital-level strategies initiating vasopressin infusion at a lower threshold vs a higher threshold on outcomes in patients with septic shock.

DESIGN, SETTING, AND PARTICIPANTS: Cluster-randomized, cluster-crossover, pragmatic clinical strategy trial including adult patients receiving vasopressors for septic shock at 13 hospitals in Idaho and Utah from February 1, 2024, to July 31, 2025. The last day of follow-up for the primary outcome was February 17, 2026.

INTERVENTION: Hospital-level implementation of septic shock management strategies recommending fixed-dose vasopressin initiation when the total dose of other vasopressors reached 0.1 µg/kg/min of norepinephrine or equivalent (lower-threshold strategy) or when the total dose of other vasopressors reached 0.4 µg/kg/min of norepinephrine or equivalent (higher-threshold strategy). Hospitals were randomized for the first month to an initial strategy (6 hospitals to the lower threshold vs 7 hospitals to the higher threshold) and then crossed over to the alternate strategy monthly thereafter.

MAIN OUTCOMES AND MEASURES: The primary outcome of 28-day mortality and the key secondary outcome of kidney replacement therapy-free days through day 28 were analyzed using multivariable generalized linear mixed-effects models, accounting for trial site and baseline patient characteristics.

RESULTS: There were 3959 unique patients with septic shock (median age, 68 [IQR, 57 to 77] years; 1903 [48%] were female). Of the patients more likely to experience differential management under the tested hospital-level vasopressin dose strategies (maximum vasopressor dose ≥0.07 µg/kg/min of norepinephrine or equivalent), 1034 of 1521 (68.0%) cared for under the lower-threshold strategy received vasopressin compared with 651 of 1526 (42.7%) cared for under the higher-threshold strategy. In the hospital-level strategy recommending a lower-dose threshold for vasopressin initiation, the maximum vasopressor dose received prior to vasopressin initiation was a median of 0.14 (IQR, 0.10 to 0.22) µg/kg/min of norepinephrine or equivalent vs 0.34 (IQR, 0.16 to 0.42) µg/kg/min of norepinephrine or equivalent in the hospital-level strategy recommending a higher-dose threshold for vasopressin initiation. Mortality at 28 days occurred in 628 of 1975 patients (31.8%) treated with the hospital-level strategy recommending initiation of vasopressin at a lower-dose threshold of other vasopressors vs 655 of 1984 patients (33.0%) treated with the higher-threshold strategy (adjusted marginal odds ratio, 0.98 [95% CI, 0.87 to 1.06], P = .62; adjusted risk difference, -0.4 [95% CI, -2.7 to 1.3] percentage points). Patients in both strategies for vasopressin initiation had a median of 29 (IQR, -1 to 29) kidney replacement therapy-free days (adjusted marginal odds ratio, 1.01 [95% CI, 0.91 to 1.14]).

CONCLUSIONS AND RELEVANCE: In this large, pragmatic clinical trial comparing the effectiveness of 2 hospital-level strategies for second-line vasopressor management in septic shock, a strategy recommending initiation of vasopressin at a lower dose of other vasopressors did not reduce 28-day mortality compared with a strategy recommending vasopressin initiation at a higher dose of other vasopressors.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06217562.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Peltan ID, Groat D, Jacobs JR, et al. Effect of Vasopressin Initiation Threshold on Septic Shock Mortality: The VASSPR Cluster Crossover Randomized Strategy Trial. JAMA. 2026. PMID: 42872917. doi:10.1001/jama.2026.21333

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。